Intensity Therapeutics reports that data highlighting the safety and efficacy results from the company’s clinical trial of its lead product candidate, INT230-6, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, as part of an oral discussion session.
The 2020 ASCO conference is being held virtually from May 29 to May 31, 2020. The session involvimg Intensity Therapeutics is scheduled to begin at 8:00 am on May 29.